MilliporeSigma
  • Molecular and clinical roles of incretin-based drugs in patients with heart failure.

Molecular and clinical roles of incretin-based drugs in patients with heart failure.

Heart failure reviews (2018-04-24)
Bassant Orabi, Rasha Kaddoura, Amr S Omar, Cornelia Carr, Abdulaziz Alkhulaifi
ABSTRACT

Glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors produce some beneficial and deleterious effects in diabetic patients not mediated by their glycemic lowering effects, and there is a need for better understanding of the molecular basis of these effects. They possess antioxidant and anti-inflammatory effects with some direct vasodilatory action (animal and human trial data) that may indirectly influence heart failure (HF). Unlike GLP-1R agonists, signaling for HF adverse effects was observed with two DPP-4 inhibitors, saxagliptin and alogliptin. Accordingly, these drugs should be used with caution in heart failure patients.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
EHMT1 human, recombinant, expressed in E. coli, ≥63% (SDS-PAGE)